Axonics Modulation Technologies Gets $32.6M For Medical Device

Irvine-based Axonics Modulation Technologies has raised $32.6M in a Series A funding, the company announced this morning. Axonics--which is developing implantable neuromodulation technology used for treating chronic pain and overactive bladder--said the lead investor was Edmond de Rothschild Investment Partners (EdRIP), and also included NeoMed Management, Legend Capital, as well as angels. Axonics Modulation Technologies said its miniaturized implantable neuromodulation technology was licensed from Valencia, California-based medical research organization, The Alfred Mann Foundation. Financial details of that licensing deal were not announced. More information »